Category: Cardiometabolic
-
Stabilizers in ATTR-CM — tafamidis and acoramidis built the first hard-outcome standard of care, but the “next-generation” increment is not proven mortality superiority
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All efficacy figures are attributed to the sponsoring trial or company (ATTR-ACT to Pfizer/NEJM 2018; ATTRibute-CM to BridgeBio/NEJM 2024). Cross-trial comparisons are not head-to-head. The “near-complete (≥90%) stabilization” claim is…
-
The ATTR cardiomyopathy landscape — four modalities target one protein, but the siRNA-success/ASO-miss split is cross-trial, not head-to-head
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and outcome figures are attributed to the sponsoring trial or company; some are company press releases rather than peer-reviewed data (noted inline). The eplontersen result below is a…
-
Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone completes the cardio-kidney-metabolic (CKM) “three-pillar” standard of care alongside SGLT2 inhibitors and GLP-1 agonists through a non-overlapping anti-inflammatory / anti-fibrotic axis. But the real substance…
-
The clinical cost behind the finerenone headline — hyperkalemia, modest absolute benefit, and the real-world monitoring gap, by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Behind finerenone’s headline hazard ratios sits a clinical cost that is not dramatic harm but friction. Across RCTs, hyperkalemia occurs at roughly 2× the placebo…
-
Finerenone’s commercial moat (Part 3): “the only nonsteroidal MRA with hard-outcome trials” — a real but time-limited advantage boxed in on three sides
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment or medical advice. The 30-second version What. Finerenone (Bayer’s Kerendia) is currently the only nonsteroidal MRA (nsMRA) with hard-outcome RCT evidence. That single fact is its commercial moat: every competitor is on a surrogate…
-
The three-pillar combination in CKM — where the finerenone + SGLT2i + GLP-1 case is proven, and where it is still an assumption
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The “three-pillar” combination in cardio-kidney-metabolic (CKM) disease stacks three non-overlapping mechanisms — SGLT2 inhibitor (hemodynamic), GLP-1 receptor agonist (metabolic) and finerenone (anti-inflammatory / anti-fibrotic). CONFIDENCE (NEJM…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
The clinical cost behind the GLP-1 headline — reading lean-mass loss, discontinuation, rebound, and safety signals by evidence tier
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The clinical cost behind the GLP-1 headline — lean-mass loss, discontinuation, weight rebound and safety signals, separated by evidence tier. The full text now lives in the…
-
The GLP-1 commercial map (Part 3): not “who wins” but “who gets access” — the Novo–Lilly duopoly and the access bottleneck
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The GLP-1 commercial map, where the binding constraint is access and reimbursement rather than which manufacturer wins on efficacy. The full text now lives in the updated…
